Winslow Capital Management LLC Increases Holdings in Danaher Corporation $DHR

Winslow Capital Management LLC boosted its stake in Danaher Corporation (NYSE:DHR) by 0.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,461,785 shares of the conglomerate’s stock after purchasing an additional 2,775 shares during the period. Winslow Capital Management LLC owned approximately 0.20% of Danaher worth $288,761,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Howard Hughes Medical Institute bought a new position in Danaher during the 2nd quarter valued at $27,000. Red Tortoise LLC raised its stake in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares in the last quarter. Ramirez Asset Management Inc. acquired a new stake in shares of Danaher in the 2nd quarter valued at about $40,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Danaher during the second quarter worth about $51,000. Finally, Strengthening Families & Communities LLC grew its stake in Danaher by 81.4% in the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock worth $52,000 after purchasing an additional 114 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Down 0.4%

DHR stock opened at $226.20 on Monday. The stock has a market cap of $159.78 billion, a PE ratio of 46.64, a price-to-earnings-growth ratio of 4.39 and a beta of 0.89. The firm’s 50-day simple moving average is $216.22 and its 200 day simple moving average is $204.48. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.71 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is presently 26.39%.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,248 shares of company stock worth $6,609,663. 11.20% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have commented on DHR shares. Barclays increased their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. HSBC raised their price objective on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research note on Tuesday, September 2nd. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Finally, Redburn Partners set a $220.00 price target on shares of Danaher in a research report on Wednesday, October 8th. Twenty research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $245.75.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.